SYNOSIA

tablet donepezil hydrochloride: 10 mg Treatment to be evaluated after 4 weeks of treatment 5 mg 1 time per day Do not administer for less than 1 month.

Treatment to continue as long as it benefits the patient 5-10 mg 1 time per day Subject at risk of prolongation of the QT interval The information provided on drug interactions results from the synthesis of the sources consulted by the Vidal scientific team.

They do not systematically reflect the information contained in the SPCs.

They are intended for practical purposes for health professionals.

The absence of an AMI in the Vidal database must never be interpreted as proof of safety. name: DONEPEZIL TEVA 5 mg Cpr orodisp Plq/28 cip13:3400938144017 conservation: Cip: 3400938144017 Storage conditions: Before opening: for 24 months status: Deleted.

Donepezil hydrochloride tablet is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type.

Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease.

Donepezil hydrochloride tablet is indicated for the treatment of dementia of the Alzheimer's type.

Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.

Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer's disease attribute some of them to a deficiency of cholinergic neurotransmission.

Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function.

This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.

There is no evidence that donepezil alters the course of the underlying dementing process. 12.3 Pharmacokinetics Pharmacokinetics of donepezil are linear over a dose range of to 10 mg given once daily.

The rate and extent of absorption of donepezil hydrochloride tablets are not influenced by food.

Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.

Peak plasma concentrations were about 2-fold higher for donepezil hydrochloride 23 mg tablets than donepezil hydrochloride 10 mg tablets.

The elimination half life of donepezil is about 70 hours, and the mean apparent plasma clearance (Cl/F) is 0.13 to 0.19 L/hr/kg. Following multiple dose administration, donepezil accumulates in plasma by to 7 fold, and steady state is reached within 15 days.

The steady state volume of distribution is to 16 L/kg. Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1.

• acid glycoprotein (about 21%) over the concentration range of to 1000 ng/mL.

Donepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified.

Donepezil is metabolized by

CYP450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation.

Following administration of 14 C-labeled donepezil, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact donepezil (53%) and as 6-O-desmethyl donepezil (11%), which has been reported to inhibit AChE to the same extent as donepezil in vitro and was found in plasma at concentrations equal to about 20% of donepezil.

Approximately 57% and 15% of the total radioactivity was recovered in urine and feces, respectively, over a period of 10 days, while 28% remained unrecovered, with about 17% of the donepezil dose recovered in the urine as unchanged drug.

Examination of the effect of

CYP2D6 genotype in Alzheimer's patients showed differences in clearance values among CYP2D6 genotype subgroups.

When compared to the extensive metabolizers, poor metabolizers had a 31.5% slower clearance and ultra-rapid metabolizers had a 24% faster clearance.

In a study of 10 patients with stable alcoholic cirrhosis, the clearance of donepezil hydrochloride was decreased by 20% relative to 10 healthy age-and sex-matched subjects.

In a study of 11 patients with moderate to severe renal impairment (Cl C < 18 mL/min/1.73 m 2 ) the clearance of donepezil hydrochloride did not differ from 11 age.

• and sex-matched healthy subjects.

No formal pharmacokinetic study was conducted to examine age-related differences in the pharmacokinetics of donepezil hydrochloride.

Population pharmacokinetic analysis suggested that the clearance of donepezil in patients decreases with increasing age.

When compared with 65-year old subjects, 90-year old subjects have a 17% decrease in clearance, while 40.

• year old subjects have a 33% increase in clearance.

The effect of age on donepezil clearance may not be clinically significant.

No specific pharmacokinetic study was conducted to investigate the effects of gender and race on the disposition of donepezil hydrochloride.

However, retrospective pharmacokinetic analysis and population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease indicates that gender and race (Japanese and Caucasians) did not affect the clearance of donepezil hydrochloride to an important degree.

There was a relationship noted between body weight and clearance.

Over the range of body weight from 50 kg to 110 kg, clearance increased from 7.77 L/h to 14.04 L/h, with a value of 10 L/hr for 70 kg individuals.

Drug Interactions Effect of Donepezil Hydrochloride on the Metabolism of Other Drugs: No in vivo clinical trials have investigated the effect of donepezil hydrochloride on the clearance of drugs metabolized by CYP3A4 (e.g., cisapride, terfenadine) or by CYP2D6 (e.g., imipramine).

However, in vitro studies show a low rate of binding to these enzymes (mean K i about to 130 µM), that, given the therapeutic plasma concentrations of donepezil (164 nM), indicates little likelihood of interference.

Based on in vitro studies, donepezil shows little or no evidence of direct inhibition of CYP2B6, CYP2C8, and CYP2C19 at clinically relevant concentrations.

Whether donepezil hydrochloride has any potential for enzyme induction is not known.

Formal pharmacokinetic studies evaluated the potential of donepezil hydrochloride for interaction with theophylline, cimetidine, warfarin, digoxin, and ketoconazole.

No effects of donepezil hydrochloride on the pharmacokinetics of these drugs were observed.

Effect of Other Drugs on the Metabolism of Donepezil Hydrochloride: Ketoconazole and quinidine, strong inhibitors of CYP450 3A and 2D6, respectively, inhibit donepezil metabolism in vitro.

Whether there is a clinical effect of quinidine is not known.

Population pharmacokinetic analysis showed that in the presence of concomitant CYP2D6 inhibitors donepezil AUC was increased by approximately 17% to 20% in Alzheimer's disease patients taking donepezil hydrochloride and 23 mg. This represented an average effect of weak, moderate, and strong CYP2D6 inhibitors.

In a 7-day crossover study in 18 healthy volunteers, ketoconazole (200 mg q.d). increased mean donepezil (5 mg q.d). concentrations (AUC 0-24 and C max ) by 36%.

The clinical relevance of this increase in concentration is unknown.

Inducers of

CYP 3A (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil hydrochloride.

Formal pharmacokinetic studies demonstrated that the metabolism of donepezil hydrochloride is not significantly affected by concurrent administration of digoxin or cimetidine.

An in vitro study showed that donepezil was not a substrate of P-glycoprotein.

Drug displacement studies have been performed in vitro between this highly bound drug (96%) and other drugs such as furosemide, digoxin, and warfarin.

Donepezil hydrochloride at concentrations of 0.3 to 10 micrograms/mL did not affect the binding of furosemide (5 micrograms/mL), digoxin (2 ng/mL), and warfarin (3 micrograms/mL) to human albumin.

Similarly, the binding of donepezil hydrochloride to human albumin was not affected by furosemide, digoxin, and warfarin.

Donepezil is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. in vitro, an inhibitory activity on acetylcholinesterase 1000 times greater than that which it has on butyrylcholinesterase, the predominant cholinesterase outside the central nervous system.

Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.

As in any case of overdose, general supportive measures should be utilized.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse, and convulsions.

Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

Tertiary anticholinergics such as atropine may be used as an antidote for donepezil hydrochloride overdosage.

Intravenous atropine sulfate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response.

Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate.

It is not known whether donepezil hydrochloride and/or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).

Dose-related signs of toxicity in animals included reduced spontaneous movement, prone position, staggering gait, lacrimation, clonic convulsions, depressed respiration, salivation, miosis, tremors, fasciculation, and lower body surface temperature.

Known hypersensitivity to donepezil hydrochloride or to piperidine derivatives Donepezil hydrochloride is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.

Alzheimer's Disease: 5 mg to 10 mg once daily Moderate to Severe Alzheimer's Disease: 10 mg to 23 mg once daily 2.1 Dosing in Mild to Moderate Alzheimer’s Disease The recommended starting dosage of donepezil hydrochloride tablet is 5 mg administered once per day in the evening, just prior to retiring.

The maximum recommended dosage of donepezil hydrochloride tablets in patients with mild to moderate Alzheimer's disease is 10 mg per day. A dose of 10 mg should not be administered until patients have been on a daily dose of 5 mg for to 6 weeks. 2.2 Dosing in Moderate to Severe Alzheimer’s Disease The recommended starting dosage of donepezil hydrochloride tablet is 5 mg administered once per day in the evening, just prior to retiring.

The maximum recommended dosage of donepezil hydrochloride tablets in patients with moderate to severe Alzheimer's disease is 23 mg per day. A dose of 10 mg should not be administered until patients have been on a daily dose of 5 mg for to 6 weeks.

A dose of 23 mg per day should not be administered until patients have been on a daily dose of 10 mg for at least 3 months. 2.3 Administration Information Donepezil hydrochloride tablets should be taken in the evening, just prior to retiring.

Donepezil hydrochloride tablets can be taken with or without food.

The donepezil hydrochloride 23 mg tablet should not be split, crushed, or chewed.

Donepezil Hydrochloride Tablets USP Donepezil Hydrochloride Tablets USP, 23 mg are reddish brown, round, film coated tablets, containing 23 mg of donepezil hydrochloride, debossed with 'G52' on one side and 'LU' on the other side, which are supplied as follows: NDC 68180-527-06 Bottle of 30s NDC 68180-527-09 Bottle of 90s Storage: Store at 25°C (77°F); excursions permitted to to 30°C (59 to 86°F) .

Protect from moisture.

There are no adequate data on the developmental risks associated with the use of donepezil hydrochloride in pregnant women.

In animal studies, developmental toxicity was not observed when donepezil was administered to pregnant rats and rabbits during organogenesis, but administration to rats during the latter part of pregnancy and throughout lactation resulted in increased stillbirths and decreased offspring survival at clinically relevant doses.

In the

U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.

The background risks of major birth defects and miscarriage for the indicated population are unknown.

Oral administration of donepezil to pregnant rats and rabbits during the period of organogenesis did not produce any teratogenic effects at doses up to 16 mg/kg/day (approximately 6 times the maximum recommended human dose [MRHD] of 23 mg/day on a mg/m 2 basis) and 10 mg/kg/day (approximately 7 times the MRHD on a mg/m 2 basis), respectively.

Oral administration of donepezil (1, 3, 10 mg/kg/day) to rats during late gestation and throughout lactation to weaning produced an increase in stillbirths and reduced offspring survival through postpartum day at the highest dose.

The no-effect dose of 3 mg/kg/day is approximately equal to the MRHD on a mg/m 2 basis.

There are no data on the presence of donepezil or its metabolites in human milk, the effects on the breastfed infant, or on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for donepezil hydrochloride and any potential adverse effects on the breastfed infant from donepezil hydrochloride or from the underlying maternal condition.

The safety and effectiveness in pediatric patients have not been established.

Alzheimer's disease is a disorder occurring primarily in individuals over 55 years of age.

The mean age of patients enrolled in the clinical studies with donepezil hydrochloride was 73 years; 80% of these patients were between and 84 years old, and 49% of patients were at or above the age of 75.

The efficacy and safety data presented in the clinical trials section were obtained from these patients.

There were no clinically significant differences in most adverse reactions reported by patient groups ≥ 65 years old and < 65 years old.